Literature DB >> 8545289

An audit of ANCA in routine clinical practice.

J D Edgar1, S A McMillan, I N Bruce, S K Conlan.   

Abstract

We have reviewed the medical records of 301/327 consecutive patients in whom anti-neutrophil cytoplasmic antibodies (ANCA) were detected by the Regional Immunology Laboratory in Northern Ireland between January 1988 and October 1991 (45 months). We have collected data for each patient regarding age, sex, smoking habit, area of residence, and details of any other autoantibody activity. Clinical diagnosis was established, with the number of organ systems involved and the evidence for that involvement (symptomatic, biochemical, radiological, and histological). Diagnoses were divided into four groups according to their recognised vasculitic features and these were related to the pattern of immunofluorescence and maximum ANCA titre detected. The most frequent diagnosis was rheumatoid arthritis (18.2% of patients) and the connective tissue disorders as a whole accounted for 27.9% of patients. ANCA were also detected in a wide range of clinical conditions which are not associated with vasculitis and these patients were an important source of 'false-positives'. The positive predictive value (PPV) of ANCA of all patterns and titres for vasculitic conditions was 27%, however, the detection of a classical ANCA pattern at high titre (> or = 1:640) was associated with an increased PPV of 75%. The coexistence of an antinuclear antibody (ANA) reduces the PPV of both classical and perinuclear ANCA, although perinuclear ANCA with antimyeloperoxidase specificity had an improved PPV. We conclude that ANCA testing should not be used as the only screening investigation for vasculitis but should be included in a rational investigative scheme. The interpretation of a positive ANCA result must take into account the presence of other autoantibodies and the full range of non-vasculitic conditions when the clinical situation is not typical of vasculitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545289      PMCID: PMC2398263          DOI: 10.1136/pgmj.71.840.605

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  20 in total

1.  Antineutrophil cytoplasmic antibodies in rheumatoid arthritis.

Authors:  J D Edgar; A L Bell; S K Conlan; S A McMillan
Journal:  Br J Rheumatol       Date:  1992-12

2.  Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome.

Authors:  A Juby; C Johnston; P Davis; A S Russell
Journal:  Br J Rheumatol       Date:  1992-03

Review 3.  The ANCA test: its clinical relevance.

Authors:  G Ramírez; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

4.  Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection.

Authors:  J Efthimiou; G Spickett; D Lane; A Thompson
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

Review 5.  Antineutrophil cytoplasmic autoantibodies: immunobiological aspects.

Authors:  W L Gross; E Csernok; W H Schmitt
Journal:  Klin Wochenschr       Date:  1991-09-03

6.  A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.

Authors:  J A Rump; J Schölmerich; V Gross; M Roth; R Helfesrieder; A Rautmann; J Lüdemann; W L Gross; H H Peter
Journal:  Immunobiology       Date:  1990-11       Impact factor: 3.144

7.  Autoantibodies to neutrophil cytoplasmic enzymes in Felty's syndrome.

Authors:  I E Coremans; E C Hagen; E A van der Voort; F J van der Woude; M R Daha; F C Breedveld
Journal:  Clin Exp Rheumatol       Date:  1993 May-Jun       Impact factor: 4.473

Review 8.  The pathogenic role of antineutrophil cytoplasmic autoantibodies.

Authors:  B H Ewert; J C Jennette; R J Falk
Journal:  Am J Kidney Dis       Date:  1991-08       Impact factor: 8.860

9.  An association between ANCA positive renal disease and malignancy.

Authors:  J D Edgar; D P Rooney; P McNamee; T A McNeill
Journal:  Clin Nephrol       Date:  1993-07       Impact factor: 0.975

Review 10.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

View more
  7 in total

1.  ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis.

Authors:  A Harris; G Chang; M Vadas; D Gillis
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Rational requesting or rationing testing?

Authors:  R J Lock
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

3.  The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice.

Authors:  D Sinclair; M Saas; J M Stevens
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

Review 4.  The clinical utility of ANCA positivity.

Authors:  J D Edgar
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

5.  Clinical spectrum associated with positive ANCA titres in 94 consecutive patients: is there a relation with PR-3 negative c-ANCA and hypergammaglobulinaemia?

Authors:  D Blockmans; E Stevens; G Mariën; H Bobbaers
Journal:  Ann Rheum Dis       Date:  1998-03       Impact factor: 19.103

6.  Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre.

Authors:  Cyrus Chehroudi; Ronald A Booth; Nataliya Milman
Journal:  Rheumatol Int       Date:  2017-12-14       Impact factor: 2.631

7.  A diagnostic dilemma: a case report.

Authors:  David M Comer; J David M Edgar
Journal:  Cases J       Date:  2009-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.